SCHEMBL5368248

SCHEMBL5368248

CCCOc1ccc(-c2ccc(N(CCC)S(=O)(=O)c3ccc(C)c(C(=O)O)c3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 3/20 0.46
GAA P10253 1/20 0.45
PTGES O14684 2/20 0.44
KEAP1 Q14145 2/20 0.44
NFE2L2 Q16236 2/20 0.44
PRNP P04156 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.42
ESR1 P03372 1/20 0.42
RARA P10276 1/20 0.42
RARB P10826 1/20 0.42
PTPN1 P18031 1/20 0.42
MMP9 P14780 1/20 0.42
MMP13 P45452 1/20 0.42
ADAM17 P78536 1/20 0.42
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376615 0.90 PTPN1 (0.43) ALOX5GAAKEAP1NFE2L2PRNP
SCHEMBL4898232 0.81 LMNA (0.54) KEAP1NFE2L2LMNAESR1POLB
SCHEMBL4897974 0.78 LMNA (0.51) ALOX5LMNAESR1POLBALDH1A1
SCHEMBL4906411 0.78 LMNA (0.58) ALOX5PTGESLMNAKMT2AESR1
SCHEMBL4909094 0.78 LMNA (0.58) ALOX5PTGESKEAP1NFE2L2LMNA
SCHEMBL5371907 0.78 POLB (0.68) LMNAKMT2APOLBALDH1A1
SCHEMBL4906642 0.78 HCRTR2 (0.54) GAAKEAP1NFE2L2LMNAESR1
SCHEMBL5380708 0.77 ESR1 (0.52) ALOX5PTGESESR1ALDH1A1
SCHEMBL4905993 0.76 LMNA (0.56) KEAP1NFE2L2LMNAKMT2AESR1
SCHEMBL4902851 0.76 LMNA (0.59) LMNAKMT2AESR1PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP claimed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US claimed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US claimed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO claimed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD ALOX5 1965/4885GAA 1367/4885PTGES 391/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD ALOX5 2307/4885GAA 1398/4885PTGES 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.